• Bespak to increase MDI capacity at its Holmes Chapel site to support Chiesi LGWP transition

  Chiesi and Inhalation CDMO Bespak have announced an expansion of an existing partnership to increase manufacturing capacity for LGWP propellant MDIs at Bespak’s Holmes Chapel, UK site. Chiesi announced plans to launch an HFA 152a inhaler by… [Read more . . .]

• Kenox now offering clinical manufacturing for OINDPs

  US-based CDMO Kenox Pharmaceuticals announced that it is now able to offer clinical manufacturing for OINDPs and has expanded its testing services for OINDPs, including in vitro BE.  In January 2025, the company said that it… [Read more . . .]

• Glenmark’s generic equivalent of FloVent HFA fluticasone propionate MDI gets final approval from FDA

  According to Glenmark, the FDA has approved the company’s ANDA for a generic equivalent of GSK’s FloVent HFA fluticasone propionate MDI with competitive generic therapy (GGT) designation. FloVent HFA was initially approved in 2004, and… [Read more . . .]

• Rein Therapeutics restarts Phase 2 trial of LTI-03 inhaled dry powder synthetic peptide in patients with IPF

  Rein Therapeutics announced the that the first patient has been dosed in a Phase 2 study evaluating its LTI-03 caveolin-1 scaffolding domain peptide DPI in patients with idiopathic pulmonary fibrosis, with interim data expected later… [Read more . . .]

• AtaiBeckley announces plans for Phase 3 development of BPL-003 intranasal mebufotenin

  AtaiBeckley said that it completed an End‑of‑Phase 2 meeting with the FDA regarding BPL‑003 intranasal mebufotenin for the treatment of treatment‑resistant depression (TRD) and that the agency indicated that it supports the company’s plan for… [Read more . . .]

• Esperion to acquire Corstasis Therapeutics and its Enbumyst bumetanide nasal spray

• Cullgen calls off merger with Pulmatrix

• SpliSense’s SPL84 inhaled antisense oligonucleotide for CF gets early PRIME designation from the EMA

• NOFLU consortium gets HaDEA funding for development of an intranasal vaccine based on Ethris technology

• SoftOx gets approval for SIS-02 Phase 1 trial of SIS hypochlorous acid inhalation solution

More news . . .